Press release
Primary Sclerosing Cholangitis Market Growth Fuels New Therapies | Key Players: Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb
Primary Sclerosing Cholangitis (PSC)
The Primary Sclerosing Cholangitis Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?jd
Primary Sclerosing Cholangitis Market Landscape Analysis:
The Primary Sclerosing Cholangitis market includes diagnostic tools, treatment therapies, and supportive care solutions for PSC, a chronic and progressive liver disease characterized by inflammation and fibrosis of the bile ducts. This market covers pharmaceuticals, clinical services, and pipeline developments focused on managing PSC and its complications.
Strategic Players Driving the Primary Sclerosing Cholangitis Market Forward:
The major global players in the market include Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Allergan, Genfit, Pliant Therapeutics, ChemomAb Therapeutics Ltd., and Dr. Falk Pharma, among others.
Primary Sclerosing Cholangitis Market Updates: Shifting Industry Trends and Market Potential
* A notable acquisition occurred with Intercept Pharmaceuticals acquiring a boutique biotech with novel anti-fibrotic compounds targeting PSC.
* Vertex Pharmaceuticals increased R&D funding specifically for pipeline candidates addressing rare liver diseases, including PSC.
* Joint ventures between academic research centers and pharma are accelerating clinical trials for PSC, with funding surpassing $100 million globally.
Research Methodology:
The global Primary Sclerosing Cholangitis Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.
Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/primary-sclerosing-cholangitis-market?jd
Segment Covered in the Primary Sclerosing Cholangitis Market:
Global Primary Sclerosing Cholangitis (PSC) Market is segmented by Treatment (Medication-based Therapies, Bile Duct Blockages, Liver Transplantation), By Disease Stage (Early-stage PSC, Moderate-stage PSC, Advanced-stage PSC), By Patient Age (Child (0-18), Adult (18 and above)), By End-User (Hospitals, Specialty Clinics, Others).
Regional Analysis for Primary Sclerosing Cholangitis Market:
United States:
The US market dominates due to higher disease awareness, advanced diagnostics, and increased investment in rare liver disease therapeutics. The US clinical trial infrastructure and biotech investments support leading R&D activity in PSC treatments. The demand for anti-fibrotic and immunomodulatory drugs is particularly strong.
Japan:
PSC is rarer but increasing in Japan, driven by better diagnostic practices and an aging population. However, the market is smaller and more niche relative to the US, with ongoing efforts to improve therapeutic options and clinical trial activity.
Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=primary-sclerosing-cholangitis-market?jd
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?jd
Most Frequently Asked Questions in the Primary Sclerosing Cholangitis Market Research Industry:
➠ Who leads the Primary Sclerosing Cholangitis industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Primary Sclerosing Cholangitis market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Primary Sclerosing Cholangitis market growth?
➠ What are the dominant sales and distribution strategies in the Primary Sclerosing Cholangitis industry?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market Growth Fuels New Therapies | Key Players: Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb here
News-ID: 4116742 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Future of Business Jets: Integration of Hybrid-Electric Propulsion, Lightweight …
Business Jets Market size reached US$ 102.69 billion in 2024 and is expected to reach US$ 254.26billion by 2032, growing with a CAGR of 12% during the forecast period 2025-2032.
The business jets market involves manufacturing, leasing, and sales of aircraft for corporate and private travel. Jets offer flexibility, reduced travel time, and privacy for executives. Market growth is fueled by rising corporate travel demand, economic growth, and technological advancements in…
Rising Fuel Consumption in Automotive, Industrial, Marine, and Aviation Sectors …
The Global Fuel Transfer Pump Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 2.6 billion by 2030, growing with a CAGR of 4.3% during the forecast period 2024-2031.
The fuel transfer pump market includes devices used to move fuel from storage tanks to engines or vehicles efficiently. Applications span automotive, industrial, marine, and aviation sectors. Growth is supported by increasing fuel consumption and the need for…
Leak Test Equipment Market is Forecast to Reach USD 1,211.7 million by 2031, Gro …
Global Leak Test Equipment Market reached USD 692.5 million in 2022 and is expected to reach USD 1,211.7 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031.
The leak test equipment market involves instruments used to detect gas or liquid leaks in industrial, automotive, and packaging applications. It ensures product integrity, safety, and regulatory compliance. Technological trends include automated testing, high-sensitivity detectors, and non-destructive methods. Growth…
Future of the Electric Vehicle Battery Recycling Market: Strategic Investments, …
The Global Electric Vehicle Battery Recycling Market reached US$ 1.12 billion in 2024 and is expected to reach US$ 20.33 billion by 2032, growing with a CAGR of 43.67% during the forecast period 2025-2032.
The EV battery recycling market involves recovering valuable metals like lithium, cobalt, and nickel from spent batteries. Recycling reduces environmental impact and supports the circular economy. Market growth is driven by rising EV adoption and raw material…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
